Immune checkpoint inhibitors for extensive-stage small-cell lung cancer: a network meta-analysis and cost-effectiveness analysis
BackgroundDespite the established efficacy of immune checkpoint inhibitors (ICIs) in combination with chemotherapy, with or without anti-angiogenic agents, for extensive-stage small-cell lung cancer (ES-SCLC), a comprehensive comparative assessment of …